Elecoglipron
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca · Phase 1 · Recruiting · Enrollment 152
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cohort 1-Treatment Sequence A | n/r | n/r | n/r | n/r |
| Cohort 1 - Treatment Sequence B | n/r | n/r | n/r | n/r |
| Cohort 2 - Treatment Sequence C | n/r | n/r | n/r | n/r |
| Cohort 2 - Treatment Sequence D | n/r | n/r | n/r | n/r |
| Cohort 3 - Treatment Sequence E | n/r | n/r | n/r | n/r |
| Cohort 3 - Treatment Sequence F | n/r | n/r | n/r | n/r |
| Cohort 4 - Treatment Sequence G | n/r | n/r | n/r | n/r |
| Cohort 4 - Treatment Sequence H | n/r | n/r | n/r | n/r |
Not shown
- Cohort 1-Treatment Sequence A: endpoint not reported
- Cohort 1 - Treatment Sequence B: endpoint not reported
- Cohort 2 - Treatment Sequence C: endpoint not reported
- Cohort 2 - Treatment Sequence D: endpoint not reported
- Cohort 3 - Treatment Sequence E: endpoint not reported
- Cohort 3 - Treatment Sequence F: endpoint not reported
- Cohort 4 - Treatment Sequence G: endpoint not reported
- Cohort 4 - Treatment Sequence H: endpoint not reported